Person who experienced the adverse event (patient)
| Event ID | CASEID | CASEVERSION | I F COD | EVENT DT | MFR DT | INIT FDA DT | FDA DT | REPT COD | AUTH NUM | MFR NUM | MFR SNDR | LIT REF | AGE | AGE COD | AGE GRP | GNDR COD | E SUB | WT | WT COD | REPT DT | TO MFR | OCCP COD | REPORTER COUNTRY | OCCR COUNTRY |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125874816 | 12587481 | 6 | F | 201510 | 20160914 | 20160725 | 20160920 | EXP | PHJP2016JP020871 | NOVARTIS | 10.61 | YR | F | Y | 0.00000 | 20160920 | JP | JP |
Drug(s) used by person
| Event ID | CASEID | DRUG SEQ | ROLE COD | DRUGNAME | PROD AI | VAL VBM | ROUTE | DOSE VBM | CUM DOSE CHR | CUM DOSE UNIT | DECHAL | RECHAL | LOT NUM | EXP DT | NDA NUM | DOSE AMT | DOSE UNIT | DOSE FORM | DOSE FREQ |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 125874816 | 12587481 | 1 | PS | NEORAL | CYCLOSPORINE | 1 | Unknown | UNK | Y | 50715 | CAPSULE | ||||||||
| 125874816 | 12587481 | 2 | SS | NEORAL | CYCLOSPORINE | 1 | Oral | 50 MG, BID | Y | 50715 | 50 | MG | CAPSULE | BID | |||||
| 125874816 | 12587481 | 3 | SS | NEORAL | CYCLOSPORINE | 1 | Oral | 100 MG, BID | Y | 50715 | 100 | MG | CAPSULE | BID | |||||
| 125874816 | 12587481 | 4 | SS | NEORAL | CYCLOSPORINE | 1 | Oral | 25 MG, QD | Y | 50715 | 25 | MG | CAPSULE | QD | |||||
| 125874816 | 12587481 | 5 | C | METHYLPREDNISOLONE. | METHYLPREDNISOLONE | 1 | Unknown | UNK | U | 0 | |||||||||
| 125874816 | 12587481 | 6 | C | PREDNISOLONE. | PREDNISOLONE | 1 | Unknown | 15 MG, QD | 0 | 15 | MG | TABLET | QD | ||||||
| 125874816 | 12587481 | 7 | C | PREDNISOLONE. | PREDNISOLONE | 1 | Unknown | 2 MG/KG, QD | 0 | 2 | MG/KG | TABLET | QD | ||||||
| 125874816 | 12587481 | 8 | C | PREDNISOLONE. | PREDNISOLONE | 1 | Unknown | 5 MG, UNK | 0 | 5 | MG | TABLET | QD | ||||||
| 125874816 | 12587481 | 9 | C | PREDNISOLONE. | PREDNISOLONE | 1 | Unknown | 2.5 MG, QOD | 0 | 2.5 | MG | TABLET | |||||||
| 125874816 | 12587481 | 10 | C | RENIVACE | ENALAPRIL | 1 | Oral | 5 MG, QD | 0 | 5 | MG | TABLET | QD | ||||||
| 125874816 | 12587481 | 11 | C | ALFAROL | ALFACALCIDOL | 1 | Oral | 0.5 UG, QD | 0 | .5 | UG | TABLET | QD | ||||||
| 125874816 | 12587481 | 12 | C | FEBURIC | FEBUXOSTAT | 1 | Oral | 10 MG, QD | 0 | 10 | MG | TABLET | QD | ||||||
| 125874816 | 12587481 | 13 | C | RITUXIMAB | RITUXIMAB | 1 | Unknown | UNK | U | 0 |
Indications of drugs used
| Event ID | CASEID | INDI DRUG SEQ | INDI PT |
|---|---|---|---|
| 125874816 | 12587481 | 1 | Nephrotic syndrome |
| 125874816 | 12587481 | 2 | Diffuse mesangial sclerosis |
| 125874816 | 12587481 | 5 | Product used for unknown indication |
| 125874816 | 12587481 | 6 | Nephrotic syndrome |
| 125874816 | 12587481 | 7 | Diffuse mesangial sclerosis |
| 125874816 | 12587481 | 10 | Hypertension |
| 125874816 | 12587481 | 11 | Osteoporosis |
| 125874816 | 12587481 | 12 | Hyperuricaemia |
| 125874816 | 12587481 | 13 | Nephrotic syndrome |
Outcome of event
| Event ID | CASEID | OUTC COD |
|---|---|---|
| 125874816 | 12587481 | HO |
| 125874816 | 12587481 | OT |
Reactions reported
| Event ID | CASEID | DRUG REC ACT | PT |
|---|---|---|---|
| 125874816 | 12587481 | Diffuse mesangial sclerosis | |
| 125874816 | 12587481 | Nephropathy | |
| 125874816 | 12587481 | Renal impairment |
Reporting Sources (this data is often not reported and may therefore be missing here)
| no results found |
Therapies reported
| Event ID | CASEID | DSG DRUG SEQ | START DT | END DT | DUR | DUR COD |
|---|---|---|---|---|---|---|
| 125874816 | 12587481 | 2 | 201012 | 0 | ||
| 125874816 | 12587481 | 6 | 201012 | 0 | ||
| 125874816 | 12587481 | 10 | 201101 | 0 | ||
| 125874816 | 12587481 | 11 | 201101 | 0 | ||
| 125874816 | 12587481 | 12 | 201101 | 0 | ||
| 125874816 | 12587481 | 13 | 201509 | 0 |